抗体靶向治疗药物.pptxVIP

;第2页/共50页;;Mechanism of Action: Monoclonal Ab;第5页/共50页;Graphic representation of progression of monoclonal antibodies from murine to chimeric to humanized to PRIMATIZED? and human. The more human the antibody is, the less likely it will generate an immune response and the more utility it has for chronic (repeat) therapy.;第7页/共50页;与单抗偶联的常用“弹头”药物;Physical characteristics of some therapeutic radionuclides;第10页/共50页;第11页/共50页;Monoclonal antibodies in the order of FDA-approval;US and EU therapeutic mAb approvals to date;1, chimeric mAbs, all products (n = 39); 2, oncological chimeric mAbs (n = 21)